The difference between small-cell lung cancer and non-small-cell lung cancer

Lung cancer is a malignant tumour with high global morbidity and mortality rates, with small-cell and non-small-cell lung cancer being the two main types, with many differences.

In pathological form, small-cell lung cancer shows unique characteristics under microscopes. Its cancer cell size is small, it is round or ovarian, it is rare and it looks like lymphocytes. The cell nucleus is relatively large, deeply dyed and has a visible nucleotide. These cancer cells tend to be closely organized, with nesting, stripping or styling. Instead of small-cell lung cancer, there are a number of pathologies, such as gland cancer, spectrocell cancer, etc. Carcinogens of gland cancer tend to be gland samples or mammograms, which can be shown to be mucous; carcinoma of carcinoma, intercellular bridges, etc., are characterized by a marked difference between the form and small cell lung cancer.

In terms of biological behaviour, small-cell lung cancer is a highly malignant tumour with aggressive characteristics. It grows rapidly and can be widely transmitted at an early stage, often with brain, liver, bone, etc. Also, small-cell lung cancer has a strong ability to attack the surrounding tissue and can be easily abused in blood vessels, lymphophones, etc. Non-small cell lung cancer is growing at a relatively slow pace and is transmitted at a relatively late stage, especially at an early stage, with more limited conditions. This does not mean, however, that non-small cell lung cancer is not dangerous, but rather that it spread less rapidly than small cell lung cancer at an early stage.

There are also significant differences in treatment methods. Small-cell lung cancer is sensitive to chemotherapy, which is often combined at an early stage. The development of tumours can be controlled to some extent by, for example, the combination of platinum and platinum. However, because of their ease of relapse and transfer, the long-term survival rate remains low even after active treatment. In the case of small-cell lung cancer of limited duration, surgical treatment may also be considered when the leaching is effective, but the application certificate is relatively strict. Non-small-cell lung cancer is at an early stage and surgical removal is the preferred treatment if surgical conditions are met. In the case of patients who are unable to operate or are at risk of re-emergence after the surgery, a variety of means can be used, depending on the circumstances, such as chemotherapy, treatment and target-oriented treatment. For example, patients with lung gland cancer can use the corresponding target drug if there is a specific genetic mutation, e.g., EGR, ALK, which can accurately act on the specific target point of the cancer cell, with significant and relatively small side effects.

The prognosis of small cell lung cancer is poor. Because of its high degree of depravity, early displacement may occur, and even if patients receive active treatment, survival rates remain low for five years. In the case of early detection and effective treatment of non-small-cell lung cancer, the survival rate is relatively high in five years, especially for early cases of lung cancer or carcinoma, some of which can be sustained over the long term after a combination of treatments such as root surgery.

There are some similarities in clinical manifestations between small-cell and non-small-cell lung cancers, such as the possibility of coughing, crotching, chest pain, and gas shortness. However, small-cell lung cancer may be widely transmitted at an early stage, and some patients may have early symptoms associated with brain transfer, such as headaches, dizziness, nausea, vomiting, etc., or bone pain caused by bone transfer. Non-small-cell lung cancer is relatively limited at an early stage, and it is only as the condition evolves that there is a significant shift in associated manifestations.

Overall, there are significant differences between small-cell lung cancer and non-small-cell lung cancer in terms of pathology, biological behaviour, treatment and prognosis. Understanding these differences is crucial for the accurate diagnosis, the development of reasonable treatment programmes and the assessment of patient prognosis, and helps medical personnel to better combat lung cancer, a disease that is a serious threat to human health.

Lung cancer, small cell lung cancer.